{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:05:22Z","timestamp":1787317522625,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cystic fibrosis-related diabetes (CFRD) is a common comorbidity in cystic fibrosis (CF), particularly in the pediatric population. As cystic fibrosis transmembrane conductance regulator modulators (CFTRm) become widely used, there is growing interest in their potential metabolic benefits. This systematic review evaluates the effects of CFTR modulators on glucose metabolism and glycemic control in children and adolescents with CFRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Following PRISMA guidelines, we conducted a literature search in PubMed, Scopus, and Medline for all papers until 2025. Eligible studies included clinical trials, observational studies, chart reviews, and case reports focusing on pediatric patients receiving CFTRm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From almost 653 initially identified records 5 studies met inclusion criteria - 1 clinical trial, 2 observational studies and 2 case reports. Evidence suggests CFTRm may improve glucose tolerance and insulin secretion in some pediatric patients, particularly in those with preserved \u03b2-cell function or early-stage CFRD. However, results varied across studies with some showing no significant improvements in glycemic control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While early findings suggest CFTR modulators may offer metabolic benefits and potentially delay or reduce the need for insulin therapy in children CFRD, current evidence is limited. Larger, pediatric-focused clinical trials with standardized glycemic outcomes are essential to determine the long-term efficacy and safety of CFTRm in managing or preventing CFRD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1688862","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:27:58Z","timestamp":1763360878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cystic fibrosis-related diabetes in the era of modern treatment using CFTR modulators in pediatric patients\u2014a systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Anna","family":"Pietrzykowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Darmo\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Szymocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"Donocik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Tarasiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Stadnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142awa","family":"Jarosz-Chobot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000530571","article-title":"Improvements in glucose regulation in children and young people with cystic fibrosis-related diabetes following initiation of elexacaftor\/tezacaftor\/ivacaftor","volume":"97","author":"Park","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"B2","article-title":"The Clinical and Functional TRanslation of CFTR (CFTR2). @ Copyright 2011 US CF Foundation, Johns Hopkins University, The Hospital for Sick Children","year":""},{"key":"B3","volume-title":"Annual Data Report","year":"2023"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"B7","article-title":"Cystic Fibrosis Mutation Database: Contact","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B10","doi-asserted-by":"publisher","first-page":"852551","DOI":"10.3389\/fped.2022.852551","article-title":"Short-Term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"101775","DOI":"10.1016\/j.rmcr.2022.101775","article-title":"Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis","volume":"40","author":"Stekolchik","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/life14101309","article-title":"One-year effect of elexacaftor\/tezacaftor\/ivacaftor therapy on HbA1c levels and insulin requirement in patients with insulin-dependent cystic fibrosis-related diabetes: a retrospective observational study","volume":"14","author":"Bassi","year":"2024","journal-title":"Life Basel Switz"},{"key":"B13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/diabetology5060040","article-title":"Evaluation of insulin secretion and continuous glucose monitoring in patients with cystic fibrosis after initiation of transmembrane conductance regulator modulator: a 52-week prospective study","volume":"5","author":"Bayona","year":"2024","journal-title":"Diabetology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"key":"B15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jcf.2015.10.012","article-title":"CFTR Potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation","volume":"15","author":"Tsabari","year":"2016","journal-title":"J Cyst Fibros"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S1569-1993(25)00075-X","DOI":"10.1016\/j.jcf.2025.03.007","article-title":"Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Wood","year":"2025","journal-title":"J Cyst Fibros"},{"key":"B18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation\u2014the Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jcf.2017.11.016","article-title":"Effect of lumacaftor\/ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","volume":"17","author":"Thomassen","year":"2018","journal-title":"J Cyst Fibros"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1623654","DOI":"10.3389\/fendo.2025.1623654","article-title":"Effect of CFTR modulators on glucose homeostasis in children and young adults with cystic related diabetes: a systematic review","volume":"16","author":"Giordano","year":"2025","journal-title":"Front Endocrinol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1688862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:27:59Z","timestamp":1763360879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1688862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":21,"alternative-id":["10.3389\/fped.2025.1688862"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1688862","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1688862"}}